Search Results for: The Gene Editing Institute of
Articles
The Gene Editing Institute of Christiana Care’s Helen F. Graham Cancer Center & Research Institute Signs Agreement With ABS September 18, 2017
To accelerate the development of next-generation cancer therapies, the Gene Editing Institute of the Helen F. Graham Cancer Center & Research...Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy Designation for Severe Sickle Cell Disease Treatment October 16, 2023
Editas Medicine, Inc. recently announced the US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene-editing...Precision BioSciences Announces In Vivo Gene Editing Collaboration With Novartis June 22, 2022
Precision BioSciences, Inc. recently announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma….
Editas Medicine & Immatics Enter Strategic Research Collaboration & Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies & Gene Editing for the Treatment of Cancer June 7, 2022
Editas Medicine, Inc. and Immatics N.V. recently announced the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and….
GENE EDITING TECHNOLOGY - Harnessing a Cell’s Natural DNA Repair Process to Develop Medicines With Higher Levels of Precision & Durability March 1, 2022
Mariana Nacht, PhD, reviews a new gene editing approach that harnesses a cell’s natural DNA repair process, known as homologous recombination, to insert a corrective copy of the gene (or transgene) at a precise spot in a patient’s genome.
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline December 13, 2021
Precision BioSciences, Inc. recently announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion (eLD) presented at….
GENE-EDITING TECHNOLOGY - The Importance of Assessing Off-Target Effects of CRISPR Gene Editing August 31, 2020
Mark Behlke, MD, PhD, says gene editing raises legitimate questions and fears about possible risks and misuse, and given the relative technical ease and low cost of CRISPR gene editing, this is likely to find widespread use in both medicine and agriculture.
Sarepta Announces Agreement With Nationwide Children’s Hospital for Rights to its Gene Therapy Program May 13, 2019
Sarepta Therapeutics, Inc. recently announced it has recently signed an agreement with the Research Institute at Nationwide Children’s Hospital (Nationwide...Amfora Licenses Gene-Editing Technology April 3, 2019
Amfora recently announced it has reached a non-exclusive research and commercial license agreement with Corteva Agriscience, the Agriculture Division of...GENE-EDITING TECHNOLOGY - How CRISPR-Cas9 Technology Will Play a Vital Role in the Future of Human Therapeutics & Drug Discovery January 8, 2018
Kevin Holden, PhD, explores how this technology can be utilized in research efforts toward the development of new therapies and how it will play a vital role in the future of biopharma and drug discovery.
Horizon Discovery Takes Exclusive License for Novel Transposon-Based Gene-Editing Technology Platform July 6, 2017
Horizon Discovery Group plc recently announced the completion of licensing agreements with all joint patent holders to provide exclusive worldwide...Intellia Therapeutics Granted CRISPR/Cas9 Genome Editing Technology Patent April 17, 2017
Intellia Therapeutics recently announced that the European Patent Office (EPO) has decided to grant a patent broadly covering the CRISPR/Cas9...Horizon Broadens Industry-Leading Gene Editing Capabilities January 23, 2017
Horizon Discovery Group plc recently announced it has broadened its gene editing capabilities through the amendment of a pre-existing license...AMRI Licenses CRISPR-Cas9 Gene Editing Technology August 24, 2016
AMRI recently announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard...AMRI Licenses CRISPR-Cas9 Gene Editing Technology August 24, 2016
AMRI recently announced that it entered into a non-exclusive commercial license agreement with the Broad Institute of MIT and Harvard...bluebird bio Announces Global Regulatory Strategy for Gene Therapy May 13, 2015
bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases...New Mechanism for Engineering Genetic Traits Governed by Multiple Genes Paves Way for Various Advances March 18, 2015
When it comes to gene expression, scientists have so far studied one single gene at a time. A new approach...Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic ALS January 9, 2024
Verge Genomics recently announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and...Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 From Phase 1/2 BRILLIANCE Trial November 17, 2022
Editas Medicine, Inc. recently announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome...SPECIAL ROUNDTABLE - Which Trends Will Have the Most Impact on Drug Development in 2022? June 6, 2022
Drug Development & Delivery posed this question to life science leaders during a recent roundtable discussion. While their responses are varied, a common theme is that COVID-19 has left a lasting impact on the industry….
